BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int Suppl (2011) 2018;8:91-165. [PMID: 30675443 DOI: 10.1016/j.kisu.2018.06.001] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 15.3] [Reference Citation Analysis]
Number Citing Articles
1 Ambarsari CG, Hidayati EL, Hasan I, Grace A, Oswari H. Successful Treatment of Hepatitis C Virus Infection Using Direct-Acting Antiviral Agents (DAAs) in Adolescents with Kidney Transplantation: A Case Series. Int J Nephrol Renovasc Dis 2020;13:139-46. [PMID: 32606888 DOI: 10.2147/IJNRD.S248632] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Marzolini C, Livio F. Prescribing issues in elderly individuals living with HIV. Expert Rev Clin Pharmacol 2019;12:643-59. [PMID: 31155978 DOI: 10.1080/17512433.2019.1627200] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
3 Tronina O, Gotlib J, Małkowski P, Jaworski M, Panczyk M. Translation and validation study of the Polish version of the Brief Hepatitis C Knowledge Scale. PLoS One 2020;15:e0235764. [PMID: 32645071 DOI: 10.1371/journal.pone.0235764] [Reference Citation Analysis]
4 Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100:S1-S276. [PMID: 34556256 DOI: 10.1016/j.kint.2021.05.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
5 Cho SMJ, Lee H, Kim HC. Differences in prevalence of hypertension subtypes according to the 2018 Korean Society of Hypertension and 2017 American College of Cardiology/American Heart Association guidelines: The Korean National Health and Nutrition Examination Survey, 2007-2017 (KNHANES IV-VII). Clin Hypertens 2019;25:26. [PMID: 31819805 DOI: 10.1186/s40885-019-0129-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
6 Fabrizi F, Cerutti R, Messa P. Updated Evidence on the Epidemiology of Hepatitis C Virus in Hemodialysis. Pathogens 2021;10:1149. [PMID: 34578181 DOI: 10.3390/pathogens10091149] [Reference Citation Analysis]
7 Lee JJ, Chang JM, Yang LJ, Hsu CC, Lin MH, Lin MY. Trends of treated hepatitis B, hepatitis C, and tuberculosis infection in long-term hemodialysis patients in Taiwan: A nationwide survey in 2010-2018. J Formos Med Assoc 2022:S0929-6646(21)00584-2. [PMID: 34996670 DOI: 10.1016/j.jfma.2021.12.019] [Reference Citation Analysis]
8 Jadoul M, Bieber BA, Martin P, Akiba T, Nwankwo C, Arduino JM, Goodkin DA, Pisoni RL. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney Int 2019;95:939-47. [PMID: 30904068 DOI: 10.1016/j.kint.2018.11.038] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 18.0] [Reference Citation Analysis]
9 Bruchfeld A, Lindahl K. Direct acting anti-viral medications for hepatitis C: Clinical trials in patients with advanced chronic kidney disease. Semin Dial 2019;32:135-40. [PMID: 30475421 DOI: 10.1111/sdi.12762] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Rovin BH, Caster DJ, Cattran DC, Gibson KL, Hogan JJ, Moeller MJ, Roccatello D, Cheung M, Wheeler DC, Winkelmayer WC, Floege J; Conference Participants. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2019;95:281-95. [PMID: 30665569 DOI: 10.1016/j.kint.2018.11.008] [Cited by in Crossref: 63] [Cited by in F6Publishing: 44] [Article Influence: 31.5] [Reference Citation Analysis]
11 Hanke AA, Sundermeier T, Boeck HT, Schieffer E, Boyen J, Braun AC, Rolff S, Stein L, Kück M, Schiffer M, Pape L, de Zwaan M, Haufe S, Kerling A, Tegtbur U, Nöhre M. Influence of Officially Ordered Restrictions During the First Wave of COVID-19 Pandemic on Physical Activity and Quality of Life in Patients after Kidney Transplantation in a Telemedicine Based Aftercare Program-A KTx360° Sub Study. Int J Environ Res Public Health 2020;17:E9144. [PMID: 33297529 DOI: 10.3390/ijerph17239144] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Cho SMJ, Lee H, Kim HC. Comparison and Implication of the Contemporary Blood Pressure Guidelines on Korean Population. Korean Circ J 2020;50:485-98. [PMID: 32212423 DOI: 10.4070/kcj.2019.0347] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Biliotti E, Palazzo D, Tinti F, D'Alessandro MD, Esvan R, Labriola R, Cappoli A, Umbro I, Volpicelli L, Bachetoni A, Villa E, Mitterhofer AP, Rucci P, Taliani G. HCV cirrhotic patients treated with direct-acting antivirals: Detection of tubular dysfunction and resolution after viral clearance. Liver Int 2021;41:158-67. [PMID: 32979012 DOI: 10.1111/liv.14672] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Emori CT, Uehara SNO, Amaral AC, Carvalho-Filho RJ, Moreira SR, Sandra de Souza E Silva I, Lanzoni VP, Silva-Souza AL, Gama RA, Soares Nunes EJ, Serra Leopércio AP, Appel F, Regina de Almeida Carvalho S, Benedito Silva AE, Medina-Pestana JO, Gomes Ferraz ML. Observational Study Evaluating the Outcome of Cirrhotic Hepatitis C Patients Submitted to Renal Transplantation. Transplant Proc 2020;52:89-96. [PMID: 32000943 DOI: 10.1016/j.transproceed.2019.10.022] [Reference Citation Analysis]
15 Liyanage L, Muzaale AD, Henderson ML, Durand CM. Living kidney donation in individuals with hepatitis C and HIV infection: rationale and emerging evidence. Curr Transplant Rep 2019;6:167-76. [PMID: 32855901 DOI: 10.1007/s40472-019-00242-5] [Reference Citation Analysis]
16 Tronina O, Durlik M, Orłowska I, Lorenc B, Łapiński TW, Garlicki A, Dybowska D, Zarębska-Michaluk D, Tudrujek-Zdunek M, Citko J, Janczewska E, Kaczmarczyk M, Jaroszewicz J, Krygier R, Klapaczyński J, Dobracka B, Białkowska-Warzecha J, Piekarska A, Simon K, Halota W, Pawłowska M, Tomasiewicz K, Flisiak R. Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study. Ann Gastroenterol 2021;34:438-46. [PMID: 33948071 DOI: 10.20524/aog.2021.0595] [Reference Citation Analysis]
17 Martynov SA, Severina AS, Larina II, Shamhalova MS, Arzumanov SV, Pinchuk AV, Shestakova MV. [Preparation of the dialysis patient with type 1 diabetes mellitus for kidney transplantation]. Probl Endokrinol (Mosk) 2020;66:18-30. [PMID: 33481364 DOI: 10.14341/probl12686] [Reference Citation Analysis]
18 Kumar R, Chan KP, Ekstrom VSM, Wong JCC, Lim KL, Ng WC, Woo SM, Chan KS, Thangaraju S, Kee TYS, Gan SSW, Foo MWY, Oon LLE, Chow WC. Hepatitis C virus antigen detection is an appropriate test for screening and early diagnosis of hepatitis C virus infection in at-risk populations and immunocompromised hosts. J Med Virol 2021;93:3738-43. [PMID: 32797627 DOI: 10.1002/jmv.26433] [Reference Citation Analysis]
19 Minutolo R, Ravera M, Cupisti A, Nappi F, Mandreoli M, Soragna G, Ferraro PM, De Nicola L; Collaborative Study Group on the Conservative Treatment of CKD of the Italian Society of Nephrology. Prevalence of hepatitis-C virus infection in non-dialysis CKD patients: a multicenter study in renal clinics. Nephrol Dial Transplant 2021:gfab190. [PMID: 34051092 DOI: 10.1093/ndt/gfab190] [Reference Citation Analysis]
20 Tiong M, Wilson S, Pham A, Chrysostomou A. Successful treatment of HIV-associated lupus-like glomerulonephritis with mycophenolic acid. Clin Case Rep 2020;8:1601-4. [PMID: 32983458 DOI: 10.1002/ccr3.2955] [Reference Citation Analysis]
21 Sikorska-Wiśniewska M, Sikorska K, Wróblewska A, Liberek T, Perkowska-Ptasińska A, Dębska-Ślizień A. Recurrence of Cryoglobulinemia Secondary to Hepatitis C in a Patient with HCV RNA (-) Negative in the Serum. Case Rep Nephrol Dial 2021;11:110-5. [PMID: 34250027 DOI: 10.1159/000515587] [Reference Citation Analysis]
22 Marticorena Garcia SR, Althoff CE, Dürr M, Halleck F, Budde K, Grittner U, Burkhardt C, Jöhrens K, Braun J, Fischer T, Hamm B, Sack I, Guo J. Tomoelastography for Longitudinal Monitoring of Viscoelasticity Changes in the Liver and in Renal Allografts after Direct-Acting Antiviral Treatment in 15 Kidney Transplant Recipients with Chronic HCV Infection. J Clin Med 2021;10:510. [PMID: 33535495 DOI: 10.3390/jcm10030510] [Reference Citation Analysis]
23 Muro K, Toda N, Yamamoto S, Yanagita M. The Successful Treatment of a Case of HCV-associated Cryoglobulinemic Glomerulonephritis with Rituximab, Direct-acting Antiviral Agents, Plasmapheresis and Long-term Steroid Despite Serologically Persistent Cryoglobulinemia. Intern Med 2021;60:583-9. [PMID: 32999232 DOI: 10.2169/internalmedicine.5461-20] [Reference Citation Analysis]
24 Fabrizi F, Alonso C, Palazzo A, Anders M, Reggiardo MV, Cheinquer H, Zuain MGV, Figueroa S, Mendizabal M, Silva M, Ridruejo E; Latin American Liver Research, Educational and Awareness Network (LALREAN). 'Real-life' experience with direct-acting antiviral agents for HCV after kidney transplant. Ann Hepatol 2021;25:100337. [PMID: 33684523 DOI: 10.1016/j.aohep.2021.100337] [Reference Citation Analysis]
25 Rajasekaran A, Franco RA, Overton ET, McGuire BM, Towns GC, Locke JE, Sawinski DL, Bell EK. Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population. Kidney Int Rep 2021;6:1788-98. [PMID: 34307975 DOI: 10.1016/j.ekir.2021.04.015] [Reference Citation Analysis]
26 Chen J, Li Y, Li G, Lei P. Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient. Ren Fail 2020;42:377-80. [PMID: 32301365 DOI: 10.1080/0886022X.2020.1753073] [Reference Citation Analysis]
27 Golla R, Kumar S, Dhibhar DP, Bhalla A, Sharma N. 0.9% saline V/S Ringer’s lactate for fluid resuscitation in adult sepsis patients in emergency medical services: An open-label randomized controlled trial. Hong Kong Journal of Emergency Medicine. [DOI: 10.1177/1024907920948983] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Chang RY, Tsai HL, Hsiao PG, Tan CW, Lee CP, Chu IT, Chen YP, Koo M. Association between heart rate recovery after exercise and renal function in patients referred for treadmill exercise test. PLoS One 2019;14:e0222236. [PMID: 31491037 DOI: 10.1371/journal.pone.0222236] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Cottone C, Bhamidimarri KR. Evaluating CKD/ESRD patient with hepatitis C infection: How to interpret diagnostic testing and assess liver injury. Semin Dial 2019;32:119-26. [PMID: 30599462 DOI: 10.1111/sdi.12760] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Constancio NS, Ferraz MLG, Martins CTB, Kraychete AC, Bitencourt PL, Nascimento MMD. Hepatitis C in Hemodialysis Units: diagnosis and therapeutic approach. J Bras Nefrol 2019;41:539-49. [PMID: 30806444 DOI: 10.1590/2175-8239-JBN-2018-0177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
31 Rovin BH, Caster DJ, Cattran DC, Gibson KL, Hogan JJ, Moeller MJ, Roccatello D, Cheung M, Wheeler DC, Winkelmayer WC, Floege J. Management and treatment of glomerular diseases (part 2): Conclusions From A Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Nefrologiâ (St -Peterbg ) 2021;25:96-119. [DOI: 10.36485/1561-6274-2021-25-1-96-119] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
32 Roth D, Bloom RD, Molnar MZ, Reese PP, Sawinski D, Sise ME, Terrault NA. KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C. Am J Kidney Dis 2020;75:665-83. [PMID: 32279907 DOI: 10.1053/j.ajkd.2019.12.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
33 Awan AA, Jadoul M, Martin P. Hepatitis C in Chronic Kidney Disease: An Overview of the KDIGO Guideline. Clin Gastroenterol Hepatol 2020;18:2158-67. [PMID: 31376491 DOI: 10.1016/j.cgh.2019.07.050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
34 Fabrizi F, Cerutti R, Porata G, Messa P, Ridruejo E. Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence. Pathogens 2019;8:E176. [PMID: 31590268 DOI: 10.3390/pathogens8040176] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
35 Tchoupe MD, Chaker H, Boudabbous M, Toumi S, Kissou FP, Gargouri S, Kammoun K, Jarraya F, Tahri N, Yaich S, Hmida MB. Treatment of chronic hepatitis C with sofosbuvir in a hemodialysis patient: a case report. Pan Afr Med J 2021;38:137. [PMID: 33912307 DOI: 10.11604/pamj.2021.38.137.20560] [Reference Citation Analysis]
36 Alcalde-bezhold G, Alcázar-arroyo R, Angoso-de-guzmán M, Arenas MD, Arias-guillén M, Arribas-cobo P, Díaz-gómez JM, García-maset R, González-parra E, Hernández-marrero D, Herrero-calvo JA, Maduell F, Molina P, Molina-núñez M, Otero-gonzález A, Pascual J, Pereira-garcía M, Pérez-garcía R, Dolores del Pino y Pino M, Prieto-velasco M, Pulido JFP, Sánchez-álvarez JE, Sánchez-hernández R, de Sequera-ortiz P. Hemodialysis Centers Guide 2020. Nefrología (English Edition) 2021;41:1-77. [DOI: 10.1016/s2013-2514(22)00042-6] [Reference Citation Analysis]
37 Konstantinidou EI, Kontekaki EG, Kefas A, Konstantinidis T, Romanidou G, Fotiadou E, Rekari V, Triantafyllidou E, Zisaki S, Kasmeridou E, Andreadou M, Kantartzi K, Mavromatidis K, Martinis G, Cassimos D, Thodis E, Panopoulou M, Mimidis K. The prevalence of HCV RNA positivity in anti-HCV antibodies-negative hemodialysis patients in Thrace Region. Multicentral study. Germs 2021;11:52-8. [PMID: 33898341 DOI: 10.18683/germs.2021.1240] [Reference Citation Analysis]
38 D'Ambrosio R, Pasulo L, Giorgini A, Spinetti A, Messina E, Fanetti I, Puoti M, Aghemo A, Viganò P, Vinci M, Menzaghi B, Lombardi A, Pan A, Pigozzi MG, Grossi P, Lazzaroni S, Spinelli O, Invernizzi P, Maggiolo F, Terreni N, Monforte AD, Poggio PD, Taddei MT, Colombo S, Pozzoni P, Molteni C, Brocchieri A, Bhoori S, Buscarini E, Centenaro R, Mendeni M, Colombo AE, Di Marco M, Dionigi E, Bella D, Borghi M, Zuin M, Zaltron S, Noventa F, Annalisa S, Lampertico P, Fagiuoli S. Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study. Dig Liver Dis 2020;52:190-8. [PMID: 31813755 DOI: 10.1016/j.dld.2019.11.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
39 Chengappa M, Herrmann S, Poonacha T. Self-reported Financial Conflict of Interest in Nephrology Clinical Practice Guidelines. Kidney Int Rep 2021;6:768-74. [PMID: 33732991 DOI: 10.1016/j.ekir.2020.12.014] [Reference Citation Analysis]
40 Skripka A, Sychev D, Bochkov P, Shevchenko R, Krupenin P, Kogay V, Listratov A, Krainyaya A, Gurinovich O, Sokolova A, Napalkov D, Fomin V. Factors Affecting Trough Plasma Dabigatran Concentrations in Patients with Atrial Fibrillation and Chronic Kidney Disease. High Blood Press Cardiovasc Prev 2020;27:151-6. [DOI: 10.1007/s40292-020-00373-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Livio F, Marzolini C. Prescribing issues in older adults living with HIV: thinking beyond drug-drug interactions with antiretroviral drugs. Ther Adv Drug Saf 2019;10:2042098619880122. [PMID: 31620274 DOI: 10.1177/2042098619880122] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
42 Amjad U, Ahmad SQ, Mir S, Ayub M. Association of anti-HCV sero-prevalence with blood transfusion and practice of haemodialysis from multiple centres in patients on maintenance haemodialysis. Pak J Med Sci 2020;36:286-9. [PMID: 32063976 DOI: 10.12669/pjms.36.2.1343] [Reference Citation Analysis]
43 Fabrizi F, Cerutti R, Dixit V, Ridruejo E. Sofosbuvir-based regimens for HCV in stage 4–stage 5 chronic kidney disease. A systematic review with meta-analysis. Nefrología (English Edition) 2021;41:578-89. [DOI: 10.1016/j.nefroe.2021.11.011] [Reference Citation Analysis]
44 Yap DYH, Liu KSH, Hsu YC, Wong GLH, Tsai MC, Chen CH, Hsu CS, Hui YT, Li MKK, Liu CH, Kan YM, Yu ML, Yuen MF. Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment. Clin Mol Hepatol 2020;26:554-61. [PMID: 32854457 DOI: 10.3350/cmh.2020.0058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Bisigniano L, Laham G, Giordani MC, Tagliafichi V, Hansen Krogh D, Maceira A, Rosa-Diez GJ. Reduced survival in patients who return to dialysis after kidney allograft failure. Clin Transplant 2020;34:e14014. [PMID: 32567723 DOI: 10.1111/ctr.14014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Cohen-Bucay A, Francis JM, Gordon CE. Progress in hepatitis C virus management in chronic kidney disease. Curr Opin Nephrol Hypertens 2021;30:493-500. [PMID: 34054074 DOI: 10.1097/MNH.0000000000000729] [Reference Citation Analysis]
47 Kamar N, Morales JM, Gordon CE, Balk EM, Jadoul M, Martin P; KDIGO HCV Work Group. Response to the KDOQI US Commentary on the 2018 KDIGO Hepatitis C Guideline. Am J Kidney Dis 2021;77:152. [PMID: 32891626 DOI: 10.1053/j.ajkd.2020.07.014] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Machado P, Gupta I, Fenkel JM, Gummadi S, Stanczak M, Wessner CE, Shaw CM, Schultz S, Soulen MC, Wallace K, Eisenbrey JR, Forsberg F. Ultrasound Pressure Estimation for Diagnosing Portal Hypertension in Patients Undergoing Dialysis for Chronic Kidney Disease. J Ultrasound Med 2021. [PMID: 34850412 DOI: 10.1002/jum.15897] [Reference Citation Analysis]
49 Ekholuenetale M, Adeyoju TO, Onuoha H, Barrow A. Renal Failure among Women of Reproductive Age in Burundi: Estimating the Prevalence and Associated Factors Using Population-Based Data. Int J Nephrol 2021;2021:6640495. [PMID: 33728065 DOI: 10.1155/2021/6640495] [Reference Citation Analysis]
50 Timofte D, Dragos D, Balcangiu-Stroescu AE, Tanasescu MD, Gabriela Balan D, Avino A, Tulin A, Stiru O, Ionescu D. Infection with hepatitis C virus in hemodialysis patients: An overview of the diagnosis and prevention rules within a hemodialysis center (Review). Exp Ther Med 2020;20:109-16. [PMID: 32509002 DOI: 10.3892/etm.2020.8606] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
51 Negro F. Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy. Cold Spring Harb Perspect Med 2020;10:a036921. [PMID: 31636094 DOI: 10.1101/cshperspect.a036921] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
52 da Mata GF, Fernandes DE, Luciano EP, Sales GTM, Riguetti MTP, Kirsztajn GM. Inflammation and kidney involvement in human viral diseases caused by SARS-CoV-2, HIV, HCV and HBV. J Venom Anim Toxins Incl Trop Dis 2021;27:e20200154. [PMID: 34381495 DOI: 10.1590/1678-9199-JVATITD-2020-0154] [Reference Citation Analysis]
53 Ji Q, Chu X, Zhou Y, Liu X, Zhao W, Ye W. Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients. J Med Virol 2021. [PMID: 34599755 DOI: 10.1002/jmv.27374] [Reference Citation Analysis]
54 Fabrizi F, Cerutti R, Silva M. HCV-infected solid organ donors, direct-acting antivirals and the current challenges. Expert Rev Clin Pharmacol 2020;13:7-14. [PMID: 31786966 DOI: 10.1080/17512433.2020.1697677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
55 Fabrizi F, Cerutti R, Messa P. An Updated View on the Antiviral Therapy of Hepatitis C in Chronic Kidney Disease. Pathogens 2021;10:1381. [PMID: 34832537 DOI: 10.3390/pathogens10111381] [Reference Citation Analysis]
56 Santiago-Hernandez A, Martinez PJ, Martin-Lorenzo M, Ruiz-Hurtado G, G Barderas M, Segura J, Ruilope LM, Alvarez-Llamas G. Differential metabolic profile associated with the condition of normoalbuminuria in the hypertensive population. Nefrologia (Engl Ed) 2020;40:440-5. [PMID: 32144010 DOI: 10.1016/j.nefro.2019.10.007] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
57 Cho SMJ, Jeon JY, Yoo TH, Lee HY, Lee YH, Kim HC. Ideal cardiovascular health duration and risk of chronic kidney disease and cardiovascular disease. Heart 2021:heartjnl-2021-320180. [PMID: 34916271 DOI: 10.1136/heartjnl-2021-320180] [Reference Citation Analysis]
58 Jadoul M, Berenguer MC, Doss W, Fabrizi F, Izopet J, Jha V, Kamar N, Kasiske BL, Lai CL, Morales JM, Patel PR, Pol S, Silva MO, Balk EM, Gordon CE, Earley A, Di M, Martin P. Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management. Kidney Int 2018;94:663-73. [PMID: 30243313 DOI: 10.1016/j.kint.2018.06.011] [Cited by in Crossref: 47] [Cited by in F6Publishing: 30] [Article Influence: 15.7] [Reference Citation Analysis]
59 Khan MU, Mahmoud MI, Butt AA. Hepatitis c virus and chronic kidney disease. Expert Rev Gastroenterol Hepatol 2020;14:579-90. [PMID: 32613874 DOI: 10.1080/17474124.2020.1776111] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
60 Gu J, Ren Z, Zhao J, Peprah FA, Xie Y, Cheng D, Wang Y, Liu H, Chu Wong CK, Zhou Y, Shi H. Calcimimetic compound NPS R-467 protects against chronic cadmium-induced mouse kidney injury by restoring autophagy process. Ecotoxicol Environ Saf 2020;189:110052. [PMID: 31830606 DOI: 10.1016/j.ecoenv.2019.110052] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
61 Fabrizi F, Cerutti R, Alfieri CM, Messa P. Updated View on Kidney Transplant from HCV-Infected Donors and DAAs. Pharmaceutics 2021;13:496. [PMID: 33917382 DOI: 10.3390/pharmaceutics13040496] [Reference Citation Analysis]
62 Fabrizi F, Cerutti R, Dixit V, Ridruejo E. Sofosbuvir-based regimens for HCV in stage 4-stage 5 chronic kidney disease. A systematic review with meta-analysis. Nefrologia 2021:S0211-6995(21)00091-6. [PMID: 34154846 DOI: 10.1016/j.nefro.2021.01.008] [Reference Citation Analysis]
63 Reese PP, Bloom RD, Roth D; KDOQI HCV Commentary Work Group. In Reply to 'Response to the KDOQI US Commentary on the 2018 KDIGO Hepatitis C Guideline'. Am J Kidney Dis 2021;77:152-3. [PMID: 32891628 DOI: 10.1053/j.ajkd.2020.08.001] [Reference Citation Analysis]
64 Goel A, Bhadauria DS, Kaul A, Verma A, Tiwari P, Rungta S, Rai P, Gupta A, Aggarwal R. Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir. Nephrol Dial Transplant 2021;36:1867-71. [PMID: 33097949 DOI: 10.1093/ndt/gfaa187] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Li PK, Bavanandan S, Mohamed R, Szeto CC, Wong VW, Chow KM, Dan YY, Huang CC, Lai CL, Tanwandee T, Teo BW, Wong GL, Yeoh EK, Iseki K, Leung CB, Park HC, Kanjanabuch T, Lu W, Fung J, Jia J, Kanda E, Law MC, Liu H, Loo CK, Mak SK, Lui SL, Tang HL, Wang AY, Yu ML, Cheung M, Jadoul M. 2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report. Kidney Int Rep 2020;5:1129-38. [PMID: 32775812 DOI: 10.1016/j.ekir.2020.05.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
66 Pérez de José A, Carbayo J, Pocurull A, Bada-Bosch T, Cases Corona CM, Shabaka A, Ramos Terrada N, Martinez Valenzuela L, Huerta A, Fernandez Lorente L, Malek-Marín TG, Goicoechea M. Direct-acting antiviral therapy improves kidney survival in hepatitis C virus-associated cryoglobulinaemia: the RENALCRYOGLOBULINEMIC study. Clin Kidney J 2021;14:586-92. [PMID: 33623683 DOI: 10.1093/ckj/sfz178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Jung JY, Yoo KD, Kang E, Kang HG, Kim SH, Kim H, Kim HJ, Park TJ, Suh SH, Jeong JC, Choi JY, Hwang YH, Choi M, Kim YL, Oh KH; Clinical Practice Guideline Work Group. Executive Summary of the Korean Society of Nephrology 2021 Clinical Practice Guideline for Optimal Hemodialysis Treatment. Kidney Res Clin Pract 2021;40:578-95. [PMID: 34922430 DOI: 10.23876/j.krcp.21.700] [Reference Citation Analysis]
68 Nakajima H, Hashimoto Y, Kaji A, Sakai R, Takahashi F, Yoshimura Y, Bamba R, Okamura T, Kitagawa N, Majima S, Senmaru T, Okada H, Nakanishi N, Ushigome E, Asano M, Hamaguchi M, Yamazaki M, Fukui M. Impact of extracellular-to-intracellular fluid volume ratio on albuminuria in patients with type 2 diabetes: A cross-sectional and longitudinal cohort study. J Diabetes Investig 2021;12:1202-11. [PMID: 33145975 DOI: 10.1111/jdi.13459] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
69 Chuaypen N, Khlaiphuengsin A, Prasoppokakorn T, Susantitaphong P, Prasithsirikul W, Avihingsanon A, Tangkijvanich P, Praditpornsilpa K. Prevalence and genotype distribution of hepatitis C virus within hemodialysis units in Thailand: role of HCV core antigen in the assessment of viremia. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07074-2] [Reference Citation Analysis]
70 Udomkarnjananun S, Naiyarakseree N, Townamchai N, Surinrat E, Tiankanon K, Banjongjit A, Vanichanan J, Jutivorakool K, Putcharoen O, Suankratay C, Surintrspanont J, Iampenkhae K, Leelahavanichkul A, Wattanatorn S, Apisutimaitri K, Burimsittichai R, Ratchanon S, Nonthasoot B, Sirichindakul B, Praditpornsilpa K, Avihingsanon Y. The first report of kidney transplantation in a human immunodeficiency virus-positive recipient in Thailand and literature review: Encouragement for developing countries in Southeast Asia. SAGE Open Med Case Rep 2021;9:2050313X211024471. [PMID: 34211716 DOI: 10.1177/2050313X211024471] [Reference Citation Analysis]